BIO-TECHNE Corp·4

Feb 3, 5:04 PM ET

McManus Matthew 4

4 · BIO-TECHNE Corp · Filed Feb 3, 2026

Research Summary

AI-generated summary of this filing

Updated

Bio-Techne (TECH) President Matthew McManus Receives Vesting RSUs

What Happened

Matthew McManus, President — Diagnostic & Spatial Bio at Bio‑Techne (TECH), had 4,621 restricted stock units (RSUs) vest and convert into shares on 2026-02-01. The RSU conversion is recorded at $0 (no cash purchase). To cover tax withholding, 1,665 of the vested shares were surrendered at an indicated price of $64.09 per share, a withholding value of $106,710. Net shares delivered to McManus after withholding: 2,956 shares.

This was an award vesting event (not an open‑market sale or purchase); share withholding for taxes is a routine settlement rather than a discretionary sale.

Key Details

  • Transaction date: 2026-02-01; Form 4 filed 2026-02-03 (timely).
  • Converted/received: 4,621 RSUs → 4,621 shares (code M, conversion of derivative) at $0.00.
  • Tax withholding: 1,665 shares disposed (code F) at $64.09 each, total $106,710.
  • Net shares retained by insider after withholding: 2,956 shares.
  • Relevant footnote(s): F1 = each RSU equals one share; F3 = 4,621 RSUs vest on 2/1/2026 (vesting schedule).
  • Transaction codes: M = exercise/conversion of derivative (RSU settlement); F = payment of tax liability via share withholding.

Context

  • This is a vesting/settlement event for RSUs — common compensation practice. The withholding of shares to cover taxes is effectively a cashless settlement and does not indicate an open‑market sale.
  • No purchase was made (not a bullish buy signal) and no discretionary sale occurred; information is primarily useful to see executive compensation being realized.
  • Filing appears timely (filed within two business days).

Insider Transaction Report

Form 4
Period: 2026-02-01
McManus Matthew
President - Diag & Spatial Bio
Transactions
  • Exercise/Conversion

    Common Stock

    2026-02-01+4,6219,356 total
  • Tax Payment

    Common Stock

    2026-02-01$64.09/sh1,665$106,7107,691 total
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F3]
    2026-02-014,6214,620 total
    Common Stock (4,621 underlying)
Holdings
  • Performance Restricted Stock Units

    [F1][F2]
    Common Stock (2,888 underlying)
    2,888
  • Performance Stock Option (Right to Buy)

    [F2]
    Exercise: $68.54Exp: 2031-02-01Common Stock (7,951 underlying)
    7,951
  • Stock Option (Right to Buy)

    [F4]
    Exercise: $68.54Exp: 2031-02-01Common Stock (15,902 underlying)
    15,902
  • Performance Restricted Stock Units

    [F1][F5]
    Common Stock (15,825 underlying)
    15,825
  • Restricted Stock Units

    [F1][F6]
    Common Stock (5,275 underlying)
    5,275
  • Stock Option (Right to Buy)

    [F7]
    Exercise: $74.91Exp: 2034-08-15Common Stock (21,320 underlying)
    21,320
  • Performance Restricted Stock Units

    [F1][F8]
    Common Stock (19,243 underlying)
    19,243
  • Restricted Stock Units

    [F1][F9]
    Common Stock (9,622 underlying)
    9,622
  • Stock Option (Right to Buy)

    [F10]
    Exercise: $53.60Exp: 2035-08-15Common Stock (24,614 underlying)
    24,614
Footnotes (10)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • [F10]Options to purchase 8,205 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,204 shares vest on 8/15/2028.
  • [F2]Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F3]4,621 restricted stock units vest on 2/1/2026 and 4,620 restricted stock units vest on 2/1/2027.
  • [F4]Options to purchase 3,976 shares vest on 2/1/2025 and 2/1/2027, and options to purchase 3,975 shares vest on 2/1/2026 and 2/1/2028.
  • [F5]Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F6]2,637 restricted stock units vest on 8/15/2026 and 2,638 restricted stock units vest on 8/15/2027.
  • [F7]Options to purchase 5,330 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
  • [F8]Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F9]3,207 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 3,208 restricted stock units vest on 8/15/2028.
Signature
/s/ Andrew Nick as Attorney-in-Fact for Matthew McManus pursuant to Power of Attorney previously filed.|2026-02-03

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES